News & Events
Announcements
10 February 2010
Proacta Founding Scientist to Speak at AACR 101st Annual Meeting, April 2010
1 February 2010
Proacta Inc Updates the PR104 Phase II Program
15 November 2009
Proacta to present at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston
31 March 2009
Proacta Inc Announces Phase II Clinical Trial of PR104
30 September 2008
Proacta Inc appoints Kevin de la Torre as Chief Financial Officer
1 August 2008
John Gutheil appointed as Chief Executive Officer
1 June, 2008
2008 ASCO Poster Presentations
Two phase I studies of PR-104 were presented at the 2008 American Society of Clinical Oncology (ASCO) meetings in Chicago, May 31 - June 3, 2008.
A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors. (PDF 530 KB)
Phase Ib study of PR-104, a hypoxia-activated alkylating agent, in combination with gemcitabine or docetaxel in patients with advanced cancer. (PDF 600 KB)
8 February, 2007
Anticancer company Proacta raises a further US$35m and extends clinical trials in New Zealand
7 February, 2007
Proacta Inc Completes $35M Series B Financing
17 May, 2006
John Gutheil, M.D., Joins Proacta as Chief Medical Officer and Senior Vice President of Clinical Affairs
24 January, 2006
Proacta Inc Announces Phase I Clinical Trial of Novel Prodrug to Target Hypoxic Tumors
21 December, 2005
NZ anticancer compound trialed at Waikato Hospital
3 March, 2005
Proacta awarded NZ$3.45m grant funding for development pipeline
1 October, 2004
Proacta Inc Reports Data at the16th EORTC-NCI-AACR Meeting in Geneva, Switzerland.
16 August, 2004
Proacta Inc, Anti-Cancer Start Up, Appoints New CEO Paul Cossum
24 June, 2004
Proacta Inc, Anti-Cancer Start Up, Raises $US8 in Series A
